Prevacid I.V. Related Published Studies
Well-designed clinical trials related to Prevacid I.V. (Lansoprazole)
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience. [2009.09.04]
A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. [2009.08]
Long-term efficacy of lansoprazole in preventing relapse of erosive reflux esophagitis. [2009.08]
Lansoprazole 15 mg once daily for 14 days is effective for treatment of frequent heartburn: results of 2 randomized, placebo-controlled, double-blind studies. [2009.07]
Lansoprazole for long-term maintenance therapy of erosive esophagitis: double-blind comparison with ranitidine. [2009.05]
Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor--evidence for dosing flexibility. [2009.04.15]
Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects. [2009.04]
Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. [2009.04]
Early effects of intravenous administrations of lansoprazole and famotidine on intragastric pH. [2009.03]
Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. [2009.02.28]
Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial Assessing the Efficacy and Safety of Proton Pump Inhibitor Lansoprazole in Infants with Symptoms of Gastroesophageal Reflux Disease. [2008.12.01]
Lansoprazole in globus pharyngeus: double-blind, randomized, placebo-controlled trial. [2008.10]
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. [2008.04]
Clinical response to 2 dosing regimens of lansoprazole in infants with gastroesophageal reflux. [2008.03]
Initial treatment with lansoprazole in young dyspeptic patients with negative urea breath test result: a randomized controlled trial with 12-month follow-up. [2007.07]
Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. [2007.05]
Effect of Helicobacter pylori infection and acid blockade by lansoprazole on clarithromycin bioavailability. [2007.03]
Acid control with esomeprazole and lansoprazole: a comparative dose-response study. [2007.02]
Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. [2007.01.15]
Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial. [2006.10]
Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection. [2006.10]
A proton pump inhibitor, lansoprazole, ameliorates asthma symptoms in asthmatic patients with gastroesophageal reflux disease. [2006.07]
Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. [2006.07]
Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve. [2006.06]
Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole. [2006.04.15]
Lansoprazole regimens that sustain intragastric pH > 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages. [2006.04.01]
Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h. [2006.04.01]
Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. [2006.02.01]
Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole. [2006.02]
Proton pump inhibitor treatment of patients with gastroesophageal reflux-related chronic cough: A comparison between two different daily doses of lansoprazole. [2006.01.07]
Intestinal CYP3A4 is not involved in the enantioselective disposition of lansoprazole. [2006.01]
Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19. [2006.01]
Comparison of the effects of single and repeated oral doses of lansoprazole and rabeprazole on ambulatory 24-hour intragastric pH in healthy volunteers. [2006]
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. [2005.11]
Treatment of patients with heartburn without endoscopic evaluation: on-demand treatment after effective continuous administration of lansoprazole 15 mg. [2005.10.01]
Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. [2005.09]
A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease. [2005.07.15]
Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status. [2005.07.01]
Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry. [2005.07]
Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. [2005.07]
Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine. [2005.06]
Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes. [2005.06]
Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. [2005.05]
Helicobacter pylori eradication using tetracycline and furazolidone versus amoxicillin and azithromycin in lansoprazole based triple therapy: an open randomized clinical trial. [2005.04]
Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. [2005.03]
Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. [2005.02.15]
Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori. [2004.12]
Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules. [2004.12]
Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. [2004.11]
Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis. [2004.10.15]
Comparison of the efficacy of 250 mg and 500 mg clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection. [2004.07.31]
Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. [2001.07]
Well-designed clinical trials possibly related to Prevacid I.V. (Lansoprazole)
Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis -- a mixed treatment comparison of randomized controlled trials. [2009.09.15]
Oxidative stress in Helicobacter pylori infection: does supplementation with vitamins C and E increase the eradication rate? [2009.08]
High efficacy of bismuth subcitrate for Helicobacter pylori eradication in pangastritis. [2009.08]
Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment. [2009.07]
Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD. [2009.04]
Controlled, household-randomized, open-label trial of the effect of treatment of Helicobacter pylori infection on iron deficiency among children in rural Alaska: results at 40 months. [2009.03.01]
Helicobacter pylori eradication in long-term proton pump inhibitor users is highly cost-effective: economic analysis of the HELPUP trial. [2008.12.01]
Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy. [2008.01]
Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. [2007.12]
Failures in a proton pump inhibitor therapeutic substitution program: lessons learned. [2007.10]
Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial. [2007.08]
Improvement in symptoms after H(2)-receptor antagonist-based therapy for eradication of H pylori infection. [2007.07.28]
High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. [2007.06]
Effects of uptake and efflux transporter inhibition on erythromycin breath test results. [2007.06]
Proton pump inhibitors: effective first-line treatment for management of dyspepsia. [2007.04]
Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. [2007.04]
Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan. [2007.03]
Effects of anti-Helicobacter pylori treatment and probiotic supplementation on intestinal microbiota. [2007.01]
High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. [2007]
A comparative study of intragastric acidity during post-breakfast and pre-dinner administration of low-dose proton pump inhibitors: a randomized three-way crossover study. [2006.11.15]
Prospective trial of laparoscopic nissen fundoplication versus proton pump inhibitor therapy for gastroesophageal reflux disease: Seven-year follow-up. [2006.11]
Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs. [2006.09.01]
The effect of CYP2C19 substrate on the metabolism of melatonin in the elderly: A randomized, double-blind, placebo-controlled study. [2006.09]
Pharmacoeconomic comparison of Helicobacter pylori eradication regimens. [2006.08]
Helicobacter pylori eradication versus prokinetics in the treatment of functional dyspepsia: a randomized, double-blind study. [2006.07]
Efficacy of metronidazole as second-line drug for the treatment of Helicobacter pylori Infection in the Japanese population: a multicenter study in the Tokyo Metropolitan Area. [2006.06]
Design and planned analyses of an ongoing randomized trial assessing the preventive effect of Helicobacter pylori eradication on occurrence of new gastric carcinomas after endoscopic resection. [2006.06]
Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial. [2006.03.21]
Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. [2006.02]
Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial. [2006.01]
Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: results of a 12-month randomized, double blind, placebo-controlled study. [2006.01]
Optimal maintenance therapy in patients with non-erosive reflux disease reporting mild reflux symptoms--a pilot study. [2006]
Effect of Clostridium butyricum on fecal flora in Helicobacter pylori eradication therapy. [2005.12.21]
Should we eradicate Helicobacter pylori before prescribing an NSAID? Result of a placebo-controlled study. [2005.12]
A randomized trial of triple therapy for pediatric Helicobacter pylori infection and risk factors for treatment failure in a population with a high prevalence of infection. [2005.11.01]
Randomized study of Helicobacter pylori eradication therapy and proton pump inhibitor monotherapy for idiopathic thrombocytopenic purpura. [2005.11]
Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. [2005.11]
The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. [2005.09.15]
Management of symptoms in step-down therapy of gastroesophageal reflux disease. [2005.09]
Dipyridamole bioavailability in subjects with reduced gastric acidity. [2005.07]
Quality of gastric ulcer healing evaluated by endoscopic ultrasonography. [2005.06.14]
Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial. [2005.05.15]
Efficacy of triple therapy plus cetraxate for the Helicobacter pylori eradication in partial gastrectomy patients. [2005.05]
[Rapidity of pain relief, medication requirement and patient satisfaction with reflux treatment in the physician's office] [2005.04.07]
First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens. [2005.03.15]
Effects of killing Helicobacter pylori quadruple therapy on peptic ulcer: a randomized double-blind clinical trial. [2005.02.21]
Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. [2005.02.15]
Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers. [2005.01]
Treatment with proton pump inhibitors in acute non-variceal upper gastrointestinal bleeding: a meta-analysis. [2005.01]
|
